Skip to content

At-home Transcranial Alternating Current Stimulation During Multitasking

At-home Transcranial Alternating Current Stimulation During Multitasking

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04231825
Enrollment
47
Registered
2020-01-18
Start date
2019-10-15
Completion date
2020-09-15
Last updated
2022-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multitasking Behavior

Brief summary

The goal is to replicate in-lab results from transcranial alternating current stimulation (tACS) with at-home tACS.

Detailed description

Participants will be assessed in-lab on multitasking and sustained attention abilities. Participants will be sent home with a tACS device to be used at-home for five days while engaged in a multitasking paradigm that is different from the multitasking outcome measure used pre/post tACS. After the at-home stimulation is complete, participants return to UCSF for a final in-lab assessment of multitasking and sustained attention ability.

Interventions

DEVICETranscranial alternating current stimulation

Transcranial alternating current stimulation across the prefrontal cortex using electrodes F3 and F4.

Sponsors

University of California, San Francisco
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

* English speaking * Grade 12 or more education * Normal or corrected to normal vision and hearing * Ability to complete cognitive tasks * Ability to cooperate and comply with all study procedures * Ability to tolerate tACS

Exclusion criteria

* Neurological or psychiatric disorders * Family history of epilepsy * History of seizures * Prior head trauma * Pregnant * Implanted electronic devices (e.g., pacemaker) * IQ \< 80 * Taking psychotropic medication * Taking anti-depressants or anti-anxiety medication * Substance abuse * Color blind * Glaucoma * Macular degeneration * Amblyopia * Strabismus

Design outcomes

Primary

MeasureTime frameDescription
Multitasking Performance Cost (Neuroracer Performance Change From Baseline)Pre-tACS and post-tACS (1 week later)Assessment of multitasking ability using change from baseline scores in d' cost (metric of discriminability). Discrimination performance (d') was measured for each participant by comparing hit (correct responses to target signs) rates and false alarm (responses to non-targets) rates and calculated as d' = Z (hits) - Z (false alarms). d' cost was then calculated as the ratio of d' during single task target discrimination task to multitask target discrimination, expressed as percentage cost.
Single Task Performance ChangePre-tACS and post-tACS (1 week later)Discrimination performance (d') was measured during single task performance for each participant by comparing hit (correct responses to target signs) rates and false alarm (responses to non-targets) rates and calculated as d' = Z (hits) - Z (false alarms). Performance data was collected during the single task condition.
Multitask Performance ChangePre-tACS and post-tACS (1 week later)Discrimination performance (d') was measured while multitasking for each participant by comparing hit (correct responses to target signs) rates and false alarm (responses to non-targets) rates and calculated as d' = Z (hits) - Z (false alarms). Performance data was collected during the multitask condition.

Secondary

MeasureTime frameDescription
Continuous Performance Test RT Change (Test of Visual Attention / Sustained Attention)Pre-tACS and post-tACS (1 week later)Assessment of sustained attention ability using response time (in ms) during the continuous performance test
Continuous Performance Test RTV Change (Test of Visual Attention / Sustained Attention)Pre-tACS and post-tACS (1 week later)Assessment of sustained attention ability using response time variability (standard deviation of response times in ms) during the continuous performance test

Countries

United States

Participant flow

Participants by arm

ArmCount
Verum Stimulation
This group will receive 6-Hz tACS Transcranial alternating current stimulation: Transcranial alternating current stimulation across the prefrontal cortex using electrodes F3 and F4.
23
Frequency Control
This group will receive 1-Hz tACS Transcranial alternating current stimulation: Transcranial alternating current stimulation across the prefrontal cortex using electrodes F3 and F4.
24
Total47

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyLost to Follow-up01
Overall StudyProtocol Violation33

Baseline characteristics

CharacteristicVerum StimulationFrequency ControlTotal
Age, Categorical
<=18 years
1 Participants1 Participants2 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
19 Participants19 Participants38 Participants
Age, Continuous25.8 years
STANDARD_DEVIATION 4.6
24.6 years
STANDARD_DEVIATION 4.2
25.2 years
STANDARD_DEVIATION 4.4
Continuous Performance Task RT322 milliseconds
STANDARD_DEVIATION 43
322 milliseconds
STANDARD_DEVIATION 34
322 milliseconds
STANDARD_DEVIATION 39
Continuous Performance Task RTV76 milliseconds
STANDARD_DEVIATION 7
65 milliseconds
STANDARD_DEVIATION 5
71 milliseconds
STANDARD_DEVIATION 6
Multitasking Cost Performance45.8 Percent change
STANDARD_DEVIATION 0.4
40.5 Percent change
STANDARD_DEVIATION 0.22
43.2 Percent change
STANDARD_DEVIATION 0.31
Multitask performance1.03 d'
STANDARD_DEVIATION 0.63
1.20 d'
STANDARD_DEVIATION 0.58
1.12 d'
STANDARD_DEVIATION 0.6
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
3 Participants4 Participants7 Participants
Race (NIH/OMB)
Black or African American
1 Participants2 Participants3 Participants
Race (NIH/OMB)
More than one race
1 Participants2 Participants3 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
15 Participants12 Participants27 Participants
Region of Enrollment
United States
20 Participants20 Participants40 Participants
Sex: Female, Male
Female
12 Participants13 Participants25 Participants
Sex: Female, Male
Male
8 Participants7 Participants15 Participants
Single Task Performance1.73 d'
STANDARD_DEVIATION 0.63
2.01 d'
STANDARD_DEVIATION 0.63
1.87 d'
STANDARD_DEVIATION 0.63

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 230 / 24
other
Total, other adverse events
1 / 232 / 24
serious
Total, serious adverse events
0 / 230 / 24

Outcome results

Primary

Multitasking Performance Cost (Neuroracer Performance Change From Baseline)

Assessment of multitasking ability using change from baseline scores in d' cost (metric of discriminability). Discrimination performance (d') was measured for each participant by comparing hit (correct responses to target signs) rates and false alarm (responses to non-targets) rates and calculated as d' = Z (hits) - Z (false alarms). d' cost was then calculated as the ratio of d' during single task target discrimination task to multitask target discrimination, expressed as percentage cost.

Time frame: Pre-tACS and post-tACS (1 week later)

Population: Only data from participants who completed the full protocol were analyzed

ArmMeasureValue (MEAN)Dispersion
Verum StimulationMultitasking Performance Cost (Neuroracer Performance Change From Baseline)45.3 percentage change of d'Standard Deviation 0.31
Frequency ControlMultitasking Performance Cost (Neuroracer Performance Change From Baseline)37.9 percentage change of d'Standard Deviation 0.27
p-value: 0.55ANCOVA
Primary

Multitask Performance Change

Discrimination performance (d') was measured while multitasking for each participant by comparing hit (correct responses to target signs) rates and false alarm (responses to non-targets) rates and calculated as d' = Z (hits) - Z (false alarms). Performance data was collected during the multitask condition.

Time frame: Pre-tACS and post-tACS (1 week later)

Population: Only data from participants who completed the full protocol were analyzed

ArmMeasureValue (MEAN)Dispersion
Verum StimulationMultitask Performance Change1.17 d'Standard Deviation 0.76
Frequency ControlMultitask Performance Change1.79 d'Standard Deviation 0.89
p-value: 0.03ANCOVA
Primary

Single Task Performance Change

Discrimination performance (d') was measured during single task performance for each participant by comparing hit (correct responses to target signs) rates and false alarm (responses to non-targets) rates and calculated as d' = Z (hits) - Z (false alarms). Performance data was collected during the single task condition.

Time frame: Pre-tACS and post-tACS (1 week later)

Population: Only data from participants who completed the full protocol were analyzed

ArmMeasureValue (MEAN)Dispersion
Verum StimulationSingle Task Performance Change1.99 d'Standard Deviation 0.94
Frequency ControlSingle Task Performance Change2.70 d'Standard Deviation 1.07
p-value: 0.02ANCOVA
Secondary

Continuous Performance Test RT Change (Test of Visual Attention / Sustained Attention)

Assessment of sustained attention ability using response time (in ms) during the continuous performance test

Time frame: Pre-tACS and post-tACS (1 week later)

Population: Only data from participants who completed the full protocol were analyzed

ArmMeasureValue (MEAN)Dispersion
Verum StimulationContinuous Performance Test RT Change (Test of Visual Attention / Sustained Attention)300 millisecondsStandard Deviation 42
Frequency ControlContinuous Performance Test RT Change (Test of Visual Attention / Sustained Attention)303 millisecondsStandard Deviation 31
p-value: 0.51ANCOVA
Secondary

Continuous Performance Test RTV Change (Test of Visual Attention / Sustained Attention)

Assessment of sustained attention ability using response time variability (standard deviation of response times in ms) during the continuous performance test

Time frame: Pre-tACS and post-tACS (1 week later)

Population: Only data from participants who completed the full protocol were analyzed

ArmMeasureValue (MEAN)Dispersion
Verum StimulationContinuous Performance Test RTV Change (Test of Visual Attention / Sustained Attention)58 millisecondsStandard Deviation 26
Frequency ControlContinuous Performance Test RTV Change (Test of Visual Attention / Sustained Attention)56 millisecondsStandard Deviation 21
p-value: 0.8ANCOVA

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026